Skip to main content

Table 2 The mean and changes of CMT in case and control groups in different follow ups

From: The effect of topical ketorolac tromethamine on macular thickening after phacoemulsification in diabetic patients

CMT (µm)

Total (n = 101)

Case (n = 49)

Control (n = 52)

Diff

95% CI

P

Mean ± SD

Median (range)

Mean ± SD

Median (range)

Mean ± SD

Median (range)

Lower

Upper

Pre

257 ± 22

258 (183 to 296)

253 ± 24

253 (183 to 294)

260 ± 20

262 (211 to 296)

-6.82

-15.75

2.10

0.11

6 W

299 ± 80

278 (172 to 602)

282 ± 56

271 (172 to 487)

312 ± 94

286 (217 to 602)

-30.08

-74.84

14.69

0.556

12 W

287 ± 48

284 (172 to 453)

279 ± 39

282 (172 to 338)

292 ± 53

285 (209 to 453)

-12.50

-41.62

16.62

0.131

24 W

282 ± 56

272 (170 to 499)

284 ± 71

270 (170 to 499)

280 ± 41

273 (213 to 409)

3.93

-37.38

45.23

0.945

Pre-6 W

34 ± 81

12 (-85 to 355)

22 ± 44

9 (-11 to 196)

44 ± 101

12 (-85 to 355)

-21.40

-68.83

26.02

0.58

P-Whitin§

  

0.006

 

0.034

     

Pre-12 W

18 ± 28

15 (-46 to 126)

12 ± 18

11 (-15 to 49)

22 ± 34

17 (-46 to 126)

-9.57

-26.80

7.65

0.322

P-Whitin§

  

< 0.001

 

0.018

     

Pre-24 W

19 ± 50

7 (-13 to 223)

23 ± 58

12 (-13 to 223)

16 ± 44

3 (-12 to 180)

7.61

-29.94

45.15

0.908

P-Whitin§

  

0.089

 

0.108

     
  1. CMT, central macular thickness; SD, standard deviation; w, weeks; Diff, difference; CI, confidence interval P, probability
  2. §Based on t-test
  3. † Based on generalized linear mixed model (GLM)